Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

t an oral presentation by Dr. Chandini Thirukkumaran of the Tom Baker Cancer Centre, Calgary, entitled "Targeting Multiple Myeloma with Oncolytic Viral Therapy" was presented at the AACR Annual Meeting. The presentation covered preclinical work using reovirus as a purging agent during autologous (harvested from the patient themselves) hematopoietic stem cell transplants for multiple myeloma. The results demonstrated that up to 70% of multiple myeloma cell lines tested showed reovirus sensitivity and reovirus induced cancer cell death mediated through apoptosis.

On April 16, 2008, we announced that Prof. Alan Melcher and his research group at St. James's University Hospital in Leeds, U.K. published the results of their work in the April 10 online issue of Gene Therapy. The paper is entitled "Inflammatory Tumour Cell Killing by Oncolytic Reovirus for the Treatment of Melanoma." The investigators showed that reovirus effectively kills and replicates in both human melanoma cell lines and freshly resected tumour. They demonstrated that reovirus melanoma killing is more potent than, and distinct from, chemotherapy or radiotherapy-induced cell death. They concluded that reovirus is suitable for clinical testing in melanoma.

RESULTS OF OPERATIONS

Net loss for the three month period ending March 31, 2008 was $3,324,241 compared to $4,113,231 for the three month period ending March 31, 2007.

Research and Development Expenses ("R&D")

2008 2007

$ $

-------------------------------------------------------------------------

Manufacturing and related process

development expenses 503,094 1,838,193

Clinical trial expenses 1,042,791 721,617

Pre-clinical trial expenses and collaborations - 106,281

O
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, the ... global corporations operating in highly regulated industries, announced ... annual Global User Group Conference, Xybion International Exchange, ... Philadelphia, Pennsylvania at the Sheraton Society ... This year,s conference theme ...
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3ORNL study reveals new characteristics of complex oxide surfaces 2ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... ... is a thermally stable, economical and high-performance solution for operations with both high and ... ... heat transfer fluid is a thermally stable, economical and high-performance solution for operations with ...
... in the September 24th issue of Nature , ... technology to explore the ancient history of India, the ... reveals that nearly all Indians carry genomic contributions from ... groups experienced periods of genetic isolation from each other ...
... , ANN ARBOR, Mich., Sept. 23 ... Research Edition version 4.2, a significant product upgrade for ... has been fully committed to supporting academic and non-profit ... features a completely redesigned user-interface, improved search and filter ...
Cached Biology Technology:Paratherm's New GLT Heat Transfer Fluid: Thermally Stable & Lower Minimum Startup Temperatures 2New research reveals the ancestral populations of India and their relationships to modern groups 2New research reveals the ancestral populations of India and their relationships to modern groups 3Compendia Bioscience Announces the Release of Oncomine 4 Research Edition 2
(Date:7/25/2014)... characterized by the existence of numerous isoforms arising ... the protein deeply different characteristics. NRG1 plays an ... development and the different phases occurring after injury ... remyelination and target reinnervation, Researchers at the University ... NRG1 upregulation observed in Schwann cells immediately after ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... sustains irreparable damage in the wake of a heart ... the cardiac muscle contains few stem cells, the tissue ... and cannot contract properly. In their search for ... exploring cardiac "patches" that could be transplanted into the ...
... The chemical is known as an "endocrine disruptor," a substance ... found in everything from plastic drink bottles to the linings ... for cash register receipts not to mention the urine ... BPA has been associated with the development of chronic diseases ...
... animal welfare concern and can cause great economic losses ... whole. A new website has been launched to help ... The website [ http://www.featherwel.org ] has been developed ... Veterinary Sciences to improve bird welfare through FeatherWel, a ...
Cached Biology News:A heart of gold 2BPA + chlorine = bad news 2New website will help farmers ensure hens maintain good feather cover 2
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... sequencing inserts cloned into M13/pUC-based plasmids, plasmids ... polymerase promoters, or lambda gt10 and gt11 ... of 0.1 µg/µl in water. The primers ... using SequiTherm™ EXCEL™ II DNA Polymerase with ...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
Biology Products: